Novartis' Rhapsido FDA Expansion Boosts Revenue Potential | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant advancements and challenges shaping these dynamic sectors.

In a notable regulatory update, the U.S. Food and Drug Administration has expanded the label for Novartis' Rhapsido to include symptomatic dermographism, based on compelling Phase 3 clinical trial data. Rhapsido, a small-molecule Bruton’s tyrosine kinase...